Prosecution Insights
Last updated: October 15, 2026

Jw Pharmaceutical Corporation

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Analysis

Jw Pharmaceutical Corporation operates a company patent portfolio within the Biotechnology & Pharmaceuticals sector. Currently, the portfolio has 1 pending office action being managed by 1 distinct examiner. This examiner is COUGHLIN, MATTHEW P, who is responsible for 1 pending office action. The activity is situated within 1 distinct art unit, reflecting a focused prosecution path.

Because there is only 1 pending office action and 1 distinct examiner, the portfolio's current interaction with the patent office is centralized. This structure allows for a direct relationship with the assigned examiner for the pending matter. With 1 pending office action total, the portfolio's current prosecution requirements are concentrated under a single examiner's review. Practitioners should note that the workload is distributed across 1 distinct art unit, suggesting a specific technical focus for the company's pending application at this time.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
COUGHLIN, MATTHEW P 1 71.4% +12.3%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18573510 NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HEMISUCCINATE COUGHLIN, MATTHEW P —

Top Art Units

Art UnitApps
1626 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18573510 NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HEMISUCCINATE COUGHLIN, MATTHEW P 1626 §112 Non-Final OA — Pending Dec 22, 2023

Managing Jw Pharmaceutical Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Jw Pharmaceutical Corporation have?

Jw Pharmaceutical Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Jw Pharmaceutical Corporation applications?

Matthew P Coughlin has the most, with 1 of Jw Pharmaceutical Corporation's pending office actions.

What technology area are Jw Pharmaceutical Corporation's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month